Dr. Mohammad Razaq, MD

Dr. Razaq practices at Mercy Hospital Oklahoma City in Oklahoma City, Oklahoma, part of Mercy.

Dr. Razaq's NPI, 1710900337, was assigned on July 25, 2006. Dr. Razaq holds Oklahoma license 28999.

Dr. Razaq's primary practice is Mercy Hospital Oklahoma City, at 4300 West Memorial Road, Oklahoma City, OK 73120 in Oklahoma County. The practice phone is (405) 755-1515.

Dr. Razaq's primary practice is Mercy Hospital Oklahoma City in Oklahoma City, Oklahoma, part of Mercy. Dr. Razaq is also affiliated with OU Health University of Oklahoma Medical Center. The medical group on file is Mercy Clinic Oklahoma Communities. Dmand AI also links Dr. Razaq to 3 more hospitals, 3 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Razaq practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Razaq's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Razaq's licenses on file in 4 states: Oklahoma, Iowa, Kansas and New York.

CMS data shows 2,244 Medicare services from Dr. Razaq across 9 procedure codes in 2024, for 572 Medicare patients. Medicare paid $140,921 for them.

CMS counts 572 Medicare patients who saw Dr. Razaq in 2024. The largest group is 65 to 74, with 231 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.10, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Razaq's median patient age at 72, with 57% women.

In 2024, Dr. Razaq wrote 1,265 Medicare Part D claims for 214 patients. 80% of them were for generic drugs. CMS names the drug for 1,023 of them, across 37 drugs with 11 or more claims each, at $2,147,330 in total drug cost. In 2023, CMS named 812 claims across 30 drugs.

Dr. Razaq accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Razaq as offering telehealth.

Dmand AI links 14 papers to Dr. Razaq, published from 2016 to 2023. 2020 was the busiest year, with 2. The most frequent topics are Lung Neoplasms, Antineoplastic Agents and Antineoplastic Combined Chemotherapy Protocols. Dr. Razaq has published most often in Am J Ther. Dr. Razaq's most frequent co-authors are Tyler Gutschenritter, MD, Vipul Gaurishankar Pareek, MD and Yan Zhao, MD.

Dmand AI links Dr. Razaq to 10 clinical trials, 5 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Carcinoma, Merkel Cell. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 538 general payments to Dr. Razaq from 59 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 68% of the total. Merck Sharp & Dohme Corporation paid the most, $154,996. It also lists 13 research payments totaling $2,320 from 2016 to 2019.